Novartis AG

NYSE:NVSUnited States

Apr 15, 2024

Show headlines and story abstract

• Novartis' Fabhalta Found to Lower Disease Marker in Kidney Disease Patients, from 3:05PM ET on Monday Apr 15, 2024 by MT Newswires

  3:05PM ET on Monday Apr 15, 2024 by MT Newswires
  Companies Mentioned: NVS
  03:05 PM EDT, 04/15/2024 (MT Newswires) -- Novartis AG (NVS) said Monday a pre-specified interim analysis of its late-stage study of Fabhalta found the medicine lowered a disease marker found in patients with a kidney disease called IgA nephropathy....

• DJ Novartis Gets Priority Review for Kidney Disease Treatment, from 2:25PM ET on Monday Apr 15, 2024 by Dow Jones

  2:25PM ET on Monday Apr 15, 2024 by Dow Jones
  Companies Mentioned: NVS
  
  By Ben Glickman
  
  Novartis said it received priority review for Fabhalta as a potential treatment for IgA nephropathy, a rare kidney disease.
  
  The pharmaceutical company said Monday that its submission to the U.S. Food and Drug Administration for potential accelerated approval of its treatment had been accepted. The company's IgA nephropathy treatment has received priority review, the company said, which means regulators are aiming to act on the application within six months.
  

• New Novartis Fabhalta(R) (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN), from 2:00PM ET on Monday Apr 15, 2024 by Dow Jones

  2:00PM ET on Monday Apr 15, 2024 by Dow Jones
  Companies Mentioned: NVS
  
  safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.